WO2005040139A2 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors - Google Patents

2-aminoaryloxazole compounds as tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2005040139A2
WO2005040139A2 PCT/IB2004/003698 IB2004003698W WO2005040139A2 WO 2005040139 A2 WO2005040139 A2 WO 2005040139A2 IB 2004003698 W IB2004003698 W IB 2004003698W WO 2005040139 A2 WO2005040139 A2 WO 2005040139A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
oxazol
methyl
ylamino
pyridin
Prior art date
Application number
PCT/IB2004/003698
Other languages
English (en)
French (fr)
Other versions
WO2005040139A3 (en
WO2005040139A8 (en
Inventor
Alain Moussy
Camille Wermuth
David Grierson
Abdellah Benjahad
Martine Croisy
Marco Ciufolini
Bruno Giethlen
Original Assignee
Ab Science
Centre National De La Recherche Scientifique (Cnrs)
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ546645A priority Critical patent/NZ546645A/en
Priority to AU2004283162A priority patent/AU2004283162B2/en
Priority to AT04791783T priority patent/ATE465731T1/de
Priority to CN2004800371595A priority patent/CN1950347B/zh
Priority to PCT/IB2004/003698 priority patent/WO2005040139A2/en
Priority to SI200431452T priority patent/SI1684750T1/sl
Priority to JP2006536215A priority patent/JP4971797B2/ja
Priority to US10/576,267 priority patent/US7718676B2/en
Priority to EP04791783A priority patent/EP1684750B1/en
Priority to PL04791783T priority patent/PL1684750T3/pl
Priority to CA2542909A priority patent/CA2542909C/en
Priority to BRPI0415467-3A priority patent/BRPI0415467A/pt
Priority to DK04791783.6T priority patent/DK1684750T3/da
Priority to KR1020067010034A priority patent/KR101164754B1/ko
Application filed by Ab Science, Centre National De La Recherche Scientifique (Cnrs), Institut Curie filed Critical Ab Science
Priority to DE602004026905T priority patent/DE602004026905D1/de
Publication of WO2005040139A2 publication Critical patent/WO2005040139A2/en
Publication of WO2005040139A3 publication Critical patent/WO2005040139A3/en
Priority to IL175028A priority patent/IL175028A/en
Priority to NO20062308A priority patent/NO20062308L/no
Publication of WO2005040139A8 publication Critical patent/WO2005040139A8/en
Priority to HK06111993.8A priority patent/HK1091134A1/xx
Priority to US12/654,957 priority patent/US8110591B2/en
Priority to HR20100326T priority patent/HRP20100326T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/IB2004/003698 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors WO2005040139A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
BRPI0415467-3A BRPI0415467A (pt) 2003-10-23 2004-10-22 compostos de 2-aminoariloxazol para o tratamento de doenças
AT04791783T ATE465731T1 (de) 2003-10-23 2004-10-22 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
CN2004800371595A CN1950347B (zh) 2003-10-23 2004-10-22 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
PCT/IB2004/003698 WO2005040139A2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
SI200431452T SI1684750T1 (sl) 2003-10-23 2004-10-22 aminoariloksazolne spojine kot inhibitorji tirozin kinaze
JP2006536215A JP4971797B2 (ja) 2003-10-23 2004-10-22 チロシンキナーゼ阻害薬としての２−アミノアリールオキサゾール化合物
AU2004283162A AU2004283162B2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
EP04791783A EP1684750B1 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
PL04791783T PL1684750T3 (pl) 2003-10-23 2004-10-22 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
CA2542909A CA2542909C (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US10/576,267 US7718676B2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
NZ546645A NZ546645A (en) 2003-10-23 2004-10-22 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
KR1020067010034A KR101164754B1 (ko) 2003-10-23 2004-10-22 티로신 키나제 억제제로서의 2-아미노아릴옥사졸 화합물
DK04791783.6T DK1684750T3 (da) 2003-10-23 2004-10-22 2-aminoaryloxazol-forbindelser som tyrosinkinase-inhibitorer
DE602004026905T DE602004026905D1 (de) 2003-10-23 2004-10-22 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
IL175028A IL175028A (en) 2003-10-23 2006-04-20 2-Aminourealoxazole compounds as tyrosine kinase inhibitors
NO20062308A NO20062308L (no) 2003-10-23 2006-05-22 2-aminoarykloksazolforbindelser som tyrosinkinasehemmere
HK06111993.8A HK1091134A1 (en) 2003-10-23 2006-11-01 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US12/654,957 US8110591B2 (en) 2003-10-23 2010-01-11 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
HR20100326T HRP20100326T1 (hr) 2003-10-23 2010-06-07 2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51321403P 2003-10-23 2003-10-23
US60/513,214 2003-10-23
PCT/IB2004/003698 WO2005040139A2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/576,267 A-371-Of-International US7718676B2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US12/654,957 Division US8110591B2 (en) 2003-10-23 2010-01-11 2-aminoaryloxazole compounds as tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
WO2005040139A2 true WO2005040139A2 (en) 2005-05-06
WO2005040139A3 WO2005040139A3 (en) 2005-10-13
WO2005040139A8 WO2005040139A8 (en) 2006-06-01

Family

ID=42827352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003698 WO2005040139A2 (en) 2003-10-23 2004-10-22 2-aminoaryloxazole compounds as tyrosine kinase inhibitors

Country Status (16)

Country Link
US (2) US7718676B2 (US08110591-20120207-C00068.png)
EP (1) EP1684750B1 (US08110591-20120207-C00068.png)
JP (1) JP4971797B2 (US08110591-20120207-C00068.png)
CN (1) CN1950347B (US08110591-20120207-C00068.png)
AT (1) ATE465731T1 (US08110591-20120207-C00068.png)
AU (1) AU2004283162B2 (US08110591-20120207-C00068.png)
BR (1) BRPI0415467A (US08110591-20120207-C00068.png)
CA (1) CA2542909C (US08110591-20120207-C00068.png)
DK (1) DK1684750T3 (US08110591-20120207-C00068.png)
HK (1) HK1091134A1 (US08110591-20120207-C00068.png)
HR (1) HRP20100326T1 (US08110591-20120207-C00068.png)
IL (1) IL175028A (US08110591-20120207-C00068.png)
NO (1) NO20062308L (US08110591-20120207-C00068.png)
NZ (1) NZ546645A (US08110591-20120207-C00068.png)
PL (1) PL1684750T3 (US08110591-20120207-C00068.png)
WO (1) WO2005040139A2 (US08110591-20120207-C00068.png)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
WO2005102325A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005112920A1 (en) * 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2006106437A2 (en) * 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
JP2006526656A (ja) * 2003-06-03 2006-11-24 ノバルティス アクチエンゲゼルシャフト ５員ヘテロ環ベースのｐ−３８阻害剤
WO2007026251A2 (en) * 2005-07-14 2007-03-08 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007076460A2 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Substituted thiazole ureas useful as inhibitors of protein kinases
WO2008084103A1 (en) * 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
WO2008090382A1 (en) * 2007-01-25 2008-07-31 The University Of Sheffield Thiazole and oxazole derivatives for use in the treatment of prion diseases, cancer and conditions of the central nervous system as well as in the regulation of stem cells
JP2010506850A (ja) * 2006-10-11 2010-03-04 デシフェラ ファーマシューティカルズ，エルエルシー 慢性骨髄増殖疾患および他の増殖性疾患の治療のために有用なキナーゼ阻害剤
WO2010055304A2 (en) 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds
EP2397138A1 (en) * 2006-04-20 2011-12-21 Janssen Pharmaceutica NV Method of inhibiting C-KIT kinase
US8272435B2 (en) 2003-05-31 2012-09-25 Cameron Systems (Ireland) Limited Apparatus and method for recovering fluids from a well and/or injecting fluids into a well
US8378095B2 (en) 2007-05-10 2013-02-19 Saruem Limited Oxazole tyrosine kinase inhibitors
US8557847B2 (en) 2005-06-10 2013-10-15 Janssen Pharmaceutica, N.V. Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
US9029352B2 (en) 2012-08-07 2015-05-12 Janssen Pharmaceutica Nv Process for the preparation of C-FMS kinase inhibitors
US9133180B2 (en) 2012-02-06 2015-09-15 Sareum Limited Aurora and FLT3 kinases modulators
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
US10882829B2 (en) 2012-03-02 2021-01-05 Sareum Limited Pharmaceutical compounds
CN113185511A (zh) * 2021-05-24 2021-07-30 中国医学科学院医药生物技术研究所 一种嘧啶类化合物及其制备方法和应用
US11154539B2 (en) 2016-10-21 2021-10-26 Sareum Limited Pharmaceutical compounds

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950347B (zh) * 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
US8066076B2 (en) 2004-02-26 2011-11-29 Cameron Systems (Ireland) Limited Connection system for subsea flow interface equipment
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2565238T3 (es) 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
PT2021335E (pt) 2006-04-20 2011-07-25 Janssen Pharmaceutica Nv Compostos heterocíclicos como inibidores de c-fms quinase
GB0618001D0 (en) 2006-09-13 2006-10-18 Des Enhanced Recovery Ltd Method
GB0625191D0 (en) 2006-12-18 2007-01-24 Des Enhanced Recovery Ltd Apparatus and method
GB0625526D0 (en) 2006-12-18 2007-01-31 Des Enhanced Recovery Ltd Apparatus and method
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2928150A1 (fr) * 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
EP2145891A1 (en) * 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2680846A4 (en) * 2011-03-01 2014-08-06 Npharmakon Llc USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH
US8551992B2 (en) 2011-05-27 2013-10-08 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
MX2014001079A (es) * 2011-07-27 2014-09-12 Ab Science Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit).
US20160175302A1 (en) * 2014-12-17 2016-06-23 Ab Science Masitinib for treating gastric cancer
EP3053920B1 (en) * 2015-02-05 2020-04-08 AB Science Compounds with anti-tumoral activity
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP4019515A1 (en) * 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2021047677A1 (zh) * 2019-09-12 2021-03-18 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
EP4200167A1 (en) * 2020-08-21 2023-06-28 Pylon Manufacturing Corp. Windshield wiper blade

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254259A2 (en) * 1986-07-21 1988-01-27 Otsuka Pharmaceutical Factory, Inc. p-Aminophenol derivatives
US5000775A (en) * 1985-12-31 1991-03-19 Monsanto Company 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes
EP0949242A1 (en) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
WO2005000298A2 (en) * 2003-06-03 2005-01-06 Novartis Ag 5-membered heterocycle-based p-38 inhibitors

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740420A (en) * 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
FR2077803B1 (US08110591-20120207-C00068.png) * 1970-02-16 1973-03-16 Innothera Lab Sa
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
CA1163561A (en) * 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) * 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
JPH0651679B2 (ja) * 1986-07-21 1994-07-06 株式会社大塚製薬工場 ｐ−アミノフェノ−ル誘導体
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5213453A (en) 1991-06-28 1993-05-25 Tapmatic Corporation Cooling systems in tapping attachments suitable for high pressure applications
GB9121418D0 (en) * 1991-10-09 1991-11-20 Nader Esfahani Rahim Imaginograph
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5906202A (en) * 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
JPH10237028A (ja) * 1996-12-24 1998-09-08 Chugai Pharmaceut Co Ltd Ｎｏｓ阻害作用を有する芳香族アミン誘導体
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
IL143920A0 (en) 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005502614A (ja) 2001-06-29 2005-01-27 アブ サイエンス 多発性硬化症（ｍｓ）を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
EP1401411A2 (en) 2001-06-29 2004-03-31 AB Science Use of tyrosine kinase inhibitors for treating bone loss
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
EP1401429A2 (en) 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
JP2004530730A (ja) 2001-06-29 2004-10-07 アブ サイエンス 腫瘍の血管新生を治療するための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用法
JP2004536097A (ja) 2001-06-29 2004-12-02 アブ サイエンス 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US20040242612A1 (en) 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
DE60225590T2 (de) 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
JP2005511596A (ja) 2001-09-20 2005-04-28 アブ サイエンス ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法
WO2003072090A2 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
WO2003072106A2 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating substance use disorders
JP2006519220A (ja) 2003-02-27 2006-08-24 アブ サイエンス 異なる型の肥満細胞症に適合可能なテイラーメイド治療方法
CN1829513A (zh) * 2003-06-03 2006-09-06 诺瓦提斯公司 基于五元杂环的p－38抑制剂
CN1950347B (zh) * 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000775A (en) * 1985-12-31 1991-03-19 Monsanto Company 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes
EP0254259A2 (en) * 1986-07-21 1988-01-27 Otsuka Pharmaceutical Factory, Inc. p-Aminophenol derivatives
EP0949242A1 (en) * 1996-12-24 1999-10-13 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibitory effect
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
WO2005000298A2 (en) * 2003-06-03 2005-01-06 Novartis Ag 5-membered heterocycle-based p-38 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MURALI DHAR T. G. ET AL.: "A modified approach to 2-(N-Aryl)-1,3-oxazoles" ORGANIC LETTERS, vol. 4, no. 12, 2002, pages 2091-2093, XP002333344 *
NATH ET AL.: "Synthesis and mercuration of some new 2-arylamino-4,5-disubstituted oxazoles as pesticides" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 20(B), no. 9, 1981, pages 827-829, XP009049725 *
RAO ET AL.: "Synthesis and fungitoxicity of substituted pyrazolyloxazole" JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 58, no. 9, 1981, pages 925-926, XP009049726 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8272435B2 (en) 2003-05-31 2012-09-25 Cameron Systems (Ireland) Limited Apparatus and method for recovering fluids from a well and/or injecting fluids into a well
JP2006526656A (ja) * 2003-06-03 2006-11-24 ノバルティス アクチエンゲゼルシャフト ５員ヘテロ環ベースのｐ−３８阻害剤
WO2005102325A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005102318A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
WO2005112920A1 (en) * 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2006106437A3 (en) * 2005-04-04 2006-11-23 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
WO2006106437A2 (en) * 2005-04-04 2006-10-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US8658659B2 (en) 2005-04-04 2014-02-25 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
CN101217954B (zh) * 2005-04-04 2013-07-10 Ab科学公司 经取代的噁唑衍生物及其作为酪氨酸激酶抑制剂的用途
JP2008534673A (ja) * 2005-04-04 2008-08-28 アブ サイエンス 置換オキサゾール誘導体、およびチロシンキナーゼ阻害薬としてのそれらの使用
EP2361624A1 (en) * 2005-04-04 2011-08-31 AB Science Oxazole derivatives and their use as tyrosine kinase inhibitors
US8557847B2 (en) 2005-06-10 2013-10-15 Janssen Pharmaceutica, N.V. Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor
WO2007026251A2 (en) * 2005-07-14 2007-03-08 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007026251A3 (en) * 2005-07-14 2007-07-12 Ab Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007076460A2 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Substituted thiazole ureas useful as inhibitors of protein kinases
WO2007076460A3 (en) * 2005-12-23 2007-08-16 Kalypsys Inc Substituted thiazole ureas useful as inhibitors of protein kinases
EP2397138A1 (en) * 2006-04-20 2011-12-21 Janssen Pharmaceutica NV Method of inhibiting C-KIT kinase
JP2010506850A (ja) * 2006-10-11 2010-03-04 デシフェラ ファーマシューティカルズ，エルエルシー 慢性骨髄増殖疾患および他の増殖性疾患の治療のために有用なキナーゼ阻害剤
WO2008084103A1 (en) * 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
US8227470B2 (en) 2007-01-12 2012-07-24 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
WO2008090382A1 (en) * 2007-01-25 2008-07-31 The University Of Sheffield Thiazole and oxazole derivatives for use in the treatment of prion diseases, cancer and conditions of the central nervous system as well as in the regulation of stem cells
US8921544B2 (en) 2007-05-10 2014-12-30 Sareum Limited Oxazole tyrosine kinase inhibitors
US8378095B2 (en) 2007-05-10 2013-02-19 Saruem Limited Oxazole tyrosine kinase inhibitors
US9187465B2 (en) 2007-05-10 2015-11-17 Sareum Limited Oxazole tyrosine kinase inhibitors
EP2170849B1 (en) * 2007-05-10 2016-12-21 Sareum Limited Oxazole tyrosine kinase inhibitors
WO2010055304A2 (en) 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds
US9133180B2 (en) 2012-02-06 2015-09-15 Sareum Limited Aurora and FLT3 kinases modulators
US10882829B2 (en) 2012-03-02 2021-01-05 Sareum Limited Pharmaceutical compounds
US11673870B2 (en) 2012-03-02 2023-06-13 Sareum Limited Pharmaceutical compounds
US9029352B2 (en) 2012-08-07 2015-05-12 Janssen Pharmaceutica Nv Process for the preparation of C-FMS kinase inhibitors
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
US11154539B2 (en) 2016-10-21 2021-10-26 Sareum Limited Pharmaceutical compounds
CN113185511A (zh) * 2021-05-24 2021-07-30 中国医学科学院医药生物技术研究所 一种嘧啶类化合物及其制备方法和应用

Also Published As

Publication number Publication date
NZ546645A (en) 2010-02-26
NO20062308L (no) 2006-05-22
HRP20100326T1 (hr) 2010-10-31
EP1684750A2 (en) 2006-08-02
US20070142390A1 (en) 2007-06-21
CA2542909C (en) 2012-07-10
PL1684750T3 (pl) 2010-10-29
WO2005040139A3 (en) 2005-10-13
IL175028A0 (en) 2006-08-20
BRPI0415467A (pt) 2006-12-19
AU2004283162A1 (en) 2005-05-06
US20100113471A1 (en) 2010-05-06
CN1950347A (zh) 2007-04-18
CN1950347B (zh) 2012-04-04
WO2005040139A8 (en) 2006-06-01
AU2004283162B2 (en) 2011-12-15
IL175028A (en) 2011-02-28
HK1091134A1 (en) 2007-01-12
JP2007509130A (ja) 2007-04-12
US7718676B2 (en) 2010-05-18
US8110591B2 (en) 2012-02-07
JP4971797B2 (ja) 2012-07-11
EP1684750B1 (en) 2010-04-28
DK1684750T3 (da) 2010-08-09
CA2542909A1 (en) 2005-05-06
ATE465731T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
EP1684750B1 (en) 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
EP1874305B1 (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
EP1711497A1 (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2006064375A9 (en) Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
EP1525200A1 (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
ES2344790T3 (es) Compuesto 2-aminoariloxazoles como inhibidores de tirosinas quinasas.
WO2007065939A1 (en) Substituted thiazole derivatives and their uses as tyrosine kinase inhibitors
US20080039466A1 (en) 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors
MXPA06004581A (en) 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
AU2003253195B2 (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA06008597A (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480037159.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007142390

Country of ref document: US

Ref document number: 10576267

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2542909

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 175028

Country of ref document: IL

Ref document number: 546645

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2206/DELNP/2006

Country of ref document: IN

Ref document number: 2004283162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004581

Country of ref document: MX

Ref document number: 2006536215

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004791783

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004283162

Country of ref document: AU

Date of ref document: 20041022

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004283162

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/04041

Country of ref document: ZA

Ref document number: 200604041

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020067010034

Country of ref document: KR

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 18/2005 UNDER (71) THE ADDRESS OF "AB SCIENCE" SHOULD READ "3, AVENUE GEORGE V"

WWP Wipo information: published in national office

Ref document number: 2004791783

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010034

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0415467

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10576267

Country of ref document: US